Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Receivables (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Receivables for 6 consecutive years, with $42.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 3.32% year-over-year to $42.2 million, compared with a TTM value of $42.2 million through Dec 2025, up 3.32%, and an annual FY2025 reading of $42.2 million, up 3.32% over the prior year.
  • Receivables was $42.2 million for Q4 2025 at Treace Medical Concepts, up from $33.0 million in the prior quarter.
  • Across five years, Receivables topped out at $42.2 million in Q4 2025 and bottomed at $10.0 million in Q2 2021.
  • Average Receivables over 5 years is $25.2 million, with a median of $25.5 million recorded in 2023.
  • The sharpest move saw Receivables soared 65.03% in 2023, then dropped 6.14% in 2024.
  • Year by year, Receivables stood at $18.6 million in 2021, then soared by 57.24% to $29.2 million in 2022, then skyrocketed by 30.5% to $38.1 million in 2023, then increased by 7.09% to $40.8 million in 2024, then increased by 3.32% to $42.2 million in 2025.
  • Business Quant data shows Receivables for TMCI at $42.2 million in Q4 2025, $33.0 million in Q3 2025, and $30.3 million in Q2 2025.